SARS-CoV-2 Papain-Like Protease Potential Inhibitors—In Silico Quantitative Assessment

SARS-CoV-2 Papain-Like Protease Potential Inhibitors—In Silico Quantitative Assessment

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) encodes the papain-like protease (PLpro). The protein not only plays an essential role in viral replication but also cleaves ubiquitin and ubiquitin-like interferon-stimulated gene 15 protein (ISG15) from host proteins, making it an import...

Full description

Bibliographic Details
Main Authors:	Adam Stasiulewicz, Alicja W. Maksymiuk, Mai Lan Nguyen, Barbara Bełza, Joanna I. Sulkowska
Format:	Article
Language:	English
Published:	MDPI AG 2021-04-01
Series:	International Journal of Molecular Sciences
Subjects:	SARS-CoV-2 COVID-19 coronavirus PLpro papain-like protease UCH-L1
Online Access:	https://www.mdpi.com/1422-0067/22/8/3957

Similar Items

A molecular sensor determines the ubiquitin substrate specificity of SARS-CoV-2 papain-like protease
by: Stephanie Patchett, et al.
Published: (2021-09-01)

Papain-Like Proteases as Coronaviral Drug Targets: Current Inhibitors, Opportunities, and Limitations
by: Anastasiia I. Petushkova, et al.
Published: (2020-09-01)

Computational study of the binding orientation and affinity of noncovalent inhibitors of the papain-like protease (PLpro) from SARS-CoV-1 considering the protein flexibility by using molecular dynamics and cross-docking
by: Luis Castillo-Campos, et al.
Published: (2023-06-01)

Screening and identification of potential MERS-CoV papain-like protease (PLpro) inhibitors; Steady-state kinetic and Molecular dynamic studies
by: Mohammed Ali Dahhas, et al.
Published: (2023-02-01)

Targeting SARS-CoV-2 Proteases for COVID-19 Antiviral Development
by: Zongyang Lv, et al.
Published: (2022-02-01)

Modeling of noncovalent inhibitors of the papain-like protease (PLpro) from SARS-CoV-2 considering the protein flexibility by using molecular dynamics and cross-docking
by: Jorge Luis Valdés-Albuernes, et al.
Published: (2024-03-01)

In silico Exploration of Inhibitors for SARS-CoV-2's Papain-Like Protease
by: Tien Huynh, et al.
Published: (2021-02-01)

SARS Virus Papain-Like Protease: A Mysterious Weapon
by: Reza Nejat, et al.
Published: (2020-07-01)

Pharmacoinformatic study of inhibitory potentials of selected flavonoids against papain-like protease and 3-chymotrypsin-like protease of SARS-CoV-2
by: Habibu Tijjani, et al.
Published: (2022-09-01)

The development of papain‐like protease from SARS‐CoV‐2, a potential drug target for antiviral screening: A review
by: Riswanto Napitupulu, et al.
Published: (2023-09-01)

Genetically Encoded Fluorescent Sensors for SARS-CoV-2 Papain-like Protease PLpro
by: Elena L. Sokolinskaya, et al.
Published: (2022-07-01)

Identification of Small Molecule Inhibitors of the Deubiquitinating Activity of the SARS-CoV-2 Papain-Like Protease: in silico Molecular Docking Studies and in vitro Enzymatic Activity Assay
by: Eleni Pitsillou, et al.
Published: (2020-12-01)

Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease
by: Roxanna Hajbabaie, et al.
Published: (2021-02-01)

Hemi-Babim and Fenoterol as Potential Inhibitors of MPro and Papain-like Protease against SARS-CoV-2: An In-Silico Study
by: Ahmad Alzamami, et al.
Published: (2022-04-01)

Study of Baicalin toward COVID-19 Treatment: In silico Target Analysis and in vitro Inhibitory Effects on SARS-CoV-2 Proteases
by: Chingju Lin, et al.
Published: (2021-11-01)

Inhibitors of Deubiquitinating Enzymes Interfere with the SARS-CoV-2 Papain-like Protease and Block Virus Replication In Vitro
by: Maximilian Große, et al.
Published: (2022-06-01)

<i>In Silico</i> Screening of Semi-Synthesized Compounds as Potential Inhibitors for SARS-CoV-2 Papain-like Protease: Pharmacophoric Features, Molecular Docking, ADMET, Toxicity and DFT Studies
by: Mohamed S. Alesawy, et al.
Published: (2021-10-01)

Supporting SARS-CoV-2 Papain-Like Protease Drug Discovery: In silico Methods and Benchmarking
by: Tamer M. Ibrahim, et al.
Published: (2020-11-01)

Discovery of Potential SARS-CoV-2 Papain-like Protease Natural Inhibitors Employing a Multi-Phase In Silico Approach
by: Eslam B. Elkaeed, et al.
Published: (2022-09-01)

Inhibitors of SARS-CoV-2 PLpro
by: Dale J. Calleja, et al.
Published: (2022-04-01)

Papain-like protease of SARS-CoV-2 inhibits RLR signaling in a deubiquitination-dependent and deubiquitination-independent manner
by: Xiang-Hong Ran, et al.
Published: (2022-08-01)

Structure determinants defining the specificity of papain-like cysteine proteases
by: Anastasiia I. Petushkova, et al.
Published: (2022-01-01)

Identification of SARS‐CoV‐2 Papain‐like Protease (PLpro) Inhibitors Using Combined Computational Approach**
by: Dr. Milan Sencanski, et al.
Published: (2022-02-01)

Potential Inhibitors Targeting Papain-Like Protease of SARS-CoV-2: Two Birds With One Stone
by: Haihai Jiang, et al.
Published: (2022-02-01)

Non-Toxic Dimeric Peptides Derived from the Bothropstoxin-I Are Potent SARS-CoV-2 and Papain-like Protease Inhibitors
by: Marjorie C. L. C. Freire, et al.
Published: (2021-08-01)

Evaluation of polyphenols from Broussonetia papyrifera as coronavirus protease inhibitors
by: Ji-Young Park, et al.
Published: (2017-01-01)

Atomistic-Level Description of the Covalent Inhibition of SARS-CoV-2 Papain-like Protease
by: Cécilia Hognon, et al.
Published: (2022-05-01)

Papain-like cysteine proteases in Carica papaya: lineage-specific gene duplication and expansion
by: Juan Liu, et al.
Published: (2018-01-01)

The Discovery of Potential SARS-CoV-2 Natural Inhibitors among 4924 African Metabolites Targeting the Papain-like Protease: A Multi-Phase In Silico Approach
by: Eslam B. Elkaeed, et al.
Published: (2022-11-01)

Potential COVID-19 papain-like protease PLpro inhibitors: repurposing FDA-approved drugs
by: Valentina L. Kouznetsova, et al.
Published: (2020-09-01)

Hepatitis E Virus Cysteine Protease Has Papain Like Properties Validated by in silico Modeling and Cell-Free Inhibition Assays
by: Shweta Saraswat, et al.
Published: (2020-01-01)

Novel nitric oxide donors are coronary vasodilators that also bind to the papain-like protease of SARS-CoV-2
by: John F. Schmedtje, Jr., et al.
Published: (2024-04-01)

Identification of Triazolopyrimidinyl Scaffold SARS-CoV-2 Papain-Like Protease (PL<sup>pro</sup>) Inhibitor
by: Sebastjan Kralj, et al.
Published: (2024-01-01)

A snake venom-analog peptide that inhibits SARS-CoV-2 and papain-like protease displays antithrombotic activity in mice arterial thrombosis model, without interfering with bleeding time
by: Ruben Siedlarczyk Nogueira, et al.
Published: (2023-01-01)

Hydrazones and Thiosemicarbazones Targeting Protein-Protein-Interactions of SARS-CoV-2 Papain-like Protease
by: Wiebke Ewert, et al.
Published: (2022-04-01)

Structure-Based Design of Potent Peptidomimetic Inhibitors Covalently Targeting SARS-CoV-2 Papain-like Protease
by: Qian Wang, et al.
Published: (2023-05-01)

Binding of SARS-CoV Covalent Non-Covalent Inhibitors to the SARS-CoV-2 Papain-Like Protease and Ovarian Tumor Domain Deubiquitinases
by: Dakshinamurthy Sivakumar, et al.
Published: (2021-05-01)

Repurposing Known Drugs as Covalent and Non-covalent Inhibitors of the SARS-CoV-2 Papain-Like Protease
by: Pietro Delre, et al.
Published: (2020-11-01)

Virtual Screening and Inhibition of Middle East Respiratory Syndrome Coronavirus Replication by Targeting Papain-like Protease
by: Mahmoud Kandeel, et al.
Published: (2021-11-01)

Repurposing of FDA Approved Drugs Against SARS-CoV-2 Papain-Like Protease: Computational, Biochemical, and in vitro Studies
by: Rajkumar Kulandaisamy, et al.
Published: (2022-05-01)